Showing 481-490 of 5234 results for "".
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of all moll…
- HintMD Launches Medical-Grade Skincare Subscriptionshttps://practicaldermatology.com/news/hintmd-launches-medical-grade-skincare-subscriptions/2457508/Medical-grade skincare subscriptions are now available through HintMD's platform. HintMD’s patent-pending software allows physicians, such as plastic surgeons and dermatologists, to turn any treatment plan into a monthly subscription payment for their patients. Skincare subscriptions allow physicia…
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 2018. The Lotion,…
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-t…
- FDA Approves Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-lyft-for-midface-injection-via-cannula/2457518/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the second cannula indication for the…
- AAD Releases New Melanoma Guidelineshttps://practicaldermatology.com/news/aad-releases-new-melanoma-guidelines/2457522/As National Healthy Skin Month begins, the American Academy of Dermatology’s (AAD) new melanoma guidelines shed light on risk of melanoma prognosis during pregnancy, the role of formal genetic testing in at-risk families and other aspects of care for primary cutaneous melanoma. The new guidelines …
- Researchers Identify Genes Involved in Skin Cancerhttps://practicaldermatology.com/news/researchers-identify-genes-involved-in-skin-cancer/2457528/Researchers at the Health Sciences department of the Universitat Jaume I (UJI) of Castellón, Spain, have identified the genes responsible for sun sensitivity and skin cancer vulnerability. The Skin Cancer Genetics and Human Pigmentation research group (Melanogén) has analysed the skin’s response to…
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectable treatments, such as Dysport (abobotulinumtoxinA), the Restylane family of fillers and Sculptra A…
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 years of follow-up, individuals with psoriasis and hypertension were 28 percent more likely to need a…
- Galderma Ups Its Aesthetic R&D Gamehttps://practicaldermatology.com/news/galderma-ups-their-aesthetic-r-d-game/2457570/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and duration; and one study focusing on t…